A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer

Purpose This phase 1 study examined safety, pharmacokinetics (PK), and efficacy of the poly(ADP-ribose) polymerase (PARP) inhibitor ABT-767 in patients with advanced solid tumors and BRCA1/2 mutations or with high-grade serous ovarian, fallopian tube, or primary peritoneal cancer. Methods Patients r...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Invest New Drugs
Hoofdauteurs: van der Biessen, Diane A. J., Gietema, Jourik A., de Jonge, Maja J. A., Desar, Ingrid M. E., den Hollander, Martha W., Dudley, Matthew, Dunbar, Martin, Hetman, Robert, Serpenti, Camille, Xiong, Hao, Mittapalli, Rajendar K., Timms, Kirsten M., Ansell, Peter, Ratajczak, Christine K., Shepherd, Stacie Peacock, van Herpen, Carla M. L.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Springer US 2018
Onderwerpen:
Phase I Studies
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6153550/
https://ncbi.nlm.nih.gov/pubmed/29313279
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-017-0551-z
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items